Atea Pharmaceuticals Shares Decline 1.9% Amid Analyst Activity

Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) experienced a decline of 1.9% on Tuesday, trading as low as $3.11 before closing at $3.14. The trading session saw approximately 325,694 shares exchanged, representing a significant drop of 19% compared to the average volume of 400,771 shares. This decline follows a previous closing price of $3.20.

Analyst Ratings and Price Targets

Recent analyst activity has provided mixed signals regarding Atea Pharmaceuticals. On October 8, 2023, Weiss Ratings reaffirmed a “sell (d-)” rating for the company. Conversely, Evercore ISI upgraded Atea to a “strong-buy” rating on November 28, 2023. Currently, one equity research analyst has rated the stock as a Strong Buy, another has given it a Buy rating, while one has issued a Hold rating, and another a Sell rating. According to data from MarketBeat.com, the consensus rating for Atea Pharmaceuticals stands at “Moderate Buy” with an average price target of $6.00.

Quarterly Earnings Report

Atea Pharmaceuticals released its quarterly earnings data on November 12, 2023, reporting an earnings per share (EPS) of ($0.53). This result fell short of analysts’ expectations, which projected an EPS of ($0.46). Analysts anticipate that Atea will report an EPS of ($2.01) for the current fiscal year.

Institutional investor activity has also influenced Atea’s stock performance. Notably, Prudential Financial Inc. acquired a new stake in Atea during the second quarter, investing approximately $36,000. Similarly, Johnson Investment Counsel Inc. purchased shares worth $55,000 in the same period.

In the third quarter, BNP Paribas Financial Markets increased its holdings in Atea by 57.7%, now owning 19,913 shares valued at $58,000 after acquiring an additional 7,286 shares. Other institutional investors, including SG Americas Securities LLC and Certified Advisory Corp, also added new positions in Atea, with respective investments of about $59,000 and $71,000. Overall, institutional investors hold approximately 86.67% of Atea’s shares.

Atea Pharmaceuticals, based in the United States, focuses on discovering, developing, and commercializing antiviral therapeutics for patients with viral infections. Its lead product candidate, AT-527, is currently undergoing a Phase 3 clinical trial known as the SUNRISE-3 trial, aimed at treating patients with COVID-19.

Investors and analysts alike will be closely monitoring further developments in Atea’s stock performance and clinical advancements in the coming months.